Ifetroban Sodium

Phase 2Small molecule

Ifetroban Sodium is one of 53 small molecule programs targeting Idiopathic Pulmonary Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary FibrosisRecruiting

Malignant Solid TumorsActive, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Recruiting

Malignant Solid TumorsPhase 2

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

Esbriet

LLegacy Health System

Approved

20 2

Medrol

Pfizer

Approved

1 3

Viagra

VViatris Specialty LLC

Approved

6 4

Remodulin

United Therapeutics

Approved

—5

Rapamune

PPrism Pharmaceuticals

Approved

1 6

Acetadote

AArbor Pharmaceuticals, Inc.

Rayos

Qvar

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Idiopathic Pulmonary Fibrosis

NCT05571059

Clinical

Trials by Indication[1]

Endothelial Function1 trial

Thromboxane Receptor Antagonist to Improve Endothelial Function

Completed·JJeffrey Rade·Phase 2·NCT03962855·57 enrolled

Malignant Solid Tumors1 trial

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Active, not recruiting·VVanderbilt-Ingram Cancer Center·Phase 2·NCT03694249·30 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting·CCumberland Pharmaceuticals·Phase 2·NCT05571059·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ifetroban Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ifetroban Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ifetroban Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cumberland Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCumberland Pharmaceuticals

Ifetroban Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Endothelial Function1 trial

Malignant Solid Tumors1 trial

Idiopathic Pulmonary Fibrosis1 trial

References

Drug Info

Quick Facts

Related News